Abstract:RNA binding proteins have emerged as central players in the mechanisms of many neurodegenerative diseases. In particular, a proteinopathy of fu sed in s arcoma (FUS) is present in some instances of familial Amyotrophic lateral sclerosis (ALS) and about 10% of sporadic Frontotemporal lobar degeneration (FTLD). Here we establish that focal injection of sonicated human FUS fibrils into brains of mice in which ALS-linked mutant or wild-type human FUS replaces endogenous mouse FUS is sufficient to induce focal cytoplasmic mislocalization and aggregation of mutant and wild-type FUS which with time spreads to distal regions of the brain. Human FUS fibril-induced FUS aggregation in the mouse brain of humanized FUS mice is accelerated by an ALS-causing FUS mutant relative to wild-type human FUS. Injection of sonicated human FUS fibrils does not induce FUS aggregation and subsequent spreading after injection into naïve mouse brains containing only mouse FUS, indicating a species barrier to human FUS aggregation and its prion-like spread. Fibril-induced human FUS aggregates recapitulate pathological features of FTLD including increased detergent insolubility of FUS and TAF15 and amyloid-like, cytoplasmic deposits of FUS that accumulate ubiquitin and p62, but not TDP-43. Finally, injection of sonicated FUS fibrils is shown to exacerbate age-dependent cognitive and behavioral deficits from mutant human FUS expression. Thus, focal seeded aggregation of FUS and further propagation through prion-like spread elicits FUS-proteinopathy and FTLD-like disease progression.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the pathological role of FUS protein in frontotemporal lobar dementia (FTLD) and its propagation mechanism. Specifically, by constructing a humanized FUS mouse model, the researchers studied whether the injection of recombinant human FUS fibrils could induce the aggregation of FUS protein and whether this aggregation could spread in the brain in a prion - like manner after injection, and ultimately lead to a disease progression similar to FTLD. ### Main problems 1. **Can the aggregation of FUS protein be induced by exogenous FUS fibril seeds?** - The researchers injected recombinant human FUS fibrils into the brains of humanized FUS mice to observe whether the aggregation of endogenous FUS protein could be induced. 2. **Can the aggregation of FUS protein spread in the brain?** - The researchers further observed whether the FUS protein aggregation could spread from the injection site to other brain regions, including the contralateral hemisphere. 3. **Will the aggregation of FUS protein lead to neurodegenerative diseases?** - The researchers evaluated whether the FUS protein aggregation would lead to neuronal dysfunction and cognitive - behavioral deficits. ### Experimental design - **Animal model**: Use humanized FUS mice, in which the endogenous mouse FUS is replaced by human wild - type or mutant FUS (such as FUSR521H). - **Experimental method**: Recombinant human FUS fibrils were injected into the cortex and hippocampus regions of the brains of 16 - month - old mice by stereotactic injection technique. - **Detection method**: The aggregation situation, propagation range of FUS protein and its impact on neurons and behavior were evaluated by means of immunofluorescence, Western Blot, behavioral tests, etc. ### Key findings 1. **FUS fibril seeds successfully induced the aggregation of endogenous FUS protein**: - After the injection of recombinant human FUS fibrils, cytoplasmic aggregation of FUS protein was observed in the mouse brains, while this did not occur in the mice injected with PBS. 2. **The aggregation of FUS protein is time - dependent and space - dependent**: - The aggregation first appeared at the injection site and then gradually spread to other brain regions, including the contralateral hemisphere. 3. **The aggregation of FUS protein led to neuronal dysfunction and cognitive - behavioral deficits**: - The mice injected with FUS fibrils showed a decline in motor coordination ability and impaired cognitive function, and these symptoms gradually worsened over time. 4. **Specificity of FUS fibrils**: - The injection of FUS monomers or SOD1 fibrils failed to induce the aggregation of FUS protein, indicating that FUS fibrils have a specific seeding effect. ### Conclusion This study confirmed that the aggregation of FUS protein can be induced by exogenous FUS fibril seeds, and this aggregation can spread in the brain in a prion - like manner, ultimately leading to neurodegenerative diseases and cognitive - behavioral deficits. This finding provides a new perspective for understanding the pathogenesis of FTLD and may provide clues for the development of treatment strategies for FUS - proteinopathies.

Frontotemporal dementia-like disease progression elicited by seeded aggregation and spread of FUS

Frontotemporal dementia-like disease progression elicited by seeded aggregation and spread of FUS

Nucleation and dissolution mechanism underlying amyotrophic lateral sclerosis/frontotemporal lobar dementia-linked fused in sarcoma condensates

Synaptic accumulation of FUS triggers age-dependent misregulation of inhibitory synapses in ALS-FUS mice

Cytoplasmic aggregation of mutant FUS causes multistep RNA splicing perturbations in the course of motor neuron pathology

Dysfunction in nonsense-mediated decay, protein homeostasis, mitochondrial function, and brain connectivity in ALS-FUS mice with cognitive deficits

FUS-regulated RNA metabolism and DNA damage repair: Implications for amyotrophic lateral sclerosis and frontotemporal dementia pathogenesis.

Expression of human FUS/TLS in yeast leads to protein aggregation and cytotoxicity, recapitulating key features of FUS proteinopathy

Molecular Determinants and Genetic Modifiers of Aggregation and Toxicity for the ALS Disease Protein FUS/TLS

Neuronal dysfunction caused by FUSR521G promotes ALS-associated phenotypes that are attenuated by NF-κB inhibition

Expression of Human FUS Protein in Drosophila Leads to Progressive Neurodegeneration

ALS/FTD Mutation-Induced Phase Transition of FUS Liquid Droplets and Reversible Hydrogels into Irreversible Hydrogels Impairs RNP Granule Function.

Abl kinase-mediated FUS Tyr526 phosphorylation alters nucleocytoplasmic FUS localization in FTLD-FUS

Aberrant Phase Separation of FUS Leads to Lysosome Sequestering and Acidification

Mutation of the ALS-/FTD-Associated RNA-Binding Protein FUS Affects Axonal Development

Investigation of a Fused in Sarcoma Splicing Mutation in a Chinese Amyotrophic Lateral Sclerosis Patient.

FUS-regulated RNA metabolism and DNA damage repair

Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis

Targeting FUS-ALS aggregation with Proteasome Inhibitors

FUS Interacts with HSP60 to Promote Mitochondrial Damage.

Mutations in FUS lead to synaptic dysregulation in ALS-iPSC derived neurons